Topixantrone, formerly known as BBR-3576, is a DNA topoisomerase inhibitor potentially for the treatment of gastric cancer and prostate cancer. References: Marini A, Berbenni V, Bruni G, Cofrancesco P, Margheritis C, Orlandi A, Villa M. Hydration, stability, and phase transformations of a new antitumor drug. J Pharm Sci. 2004 Sep;93(9):2222-31. PubMed PMID: 15295783.

纯度：≥98%

CAS：156090-18-5